MDT vs. VRTX, CI, BSX, BMY, REGN, SNY, ELV, SYK, GSK, and HCA
Should you be buying Medtronic stock or one of its competitors? The main competitors of Medtronic include Vertex Pharmaceuticals (VRTX), The Cigna Group (CI), Boston Scientific (BSX), Bristol-Myers Squibb (BMY), Regeneron Pharmaceuticals (REGN), Sanofi (SNY), Elevance Health (ELV), Stryker (SYK), GSK (GSK), and HCA Healthcare (HCA). These companies are all part of the "medical" sector.
Vertex Pharmaceuticals (NASDAQ:VRTX) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, community ranking, valuation, earnings, analyst recommendations, institutional ownership and profitability.
In the previous week, Vertex Pharmaceuticals had 24 more articles in the media than Medtronic. MarketBeat recorded 40 mentions for Vertex Pharmaceuticals and 16 mentions for Medtronic. Vertex Pharmaceuticals' average media sentiment score of 0.79 beat Medtronic's score of 0.59 indicating that Medtronic is being referred to more favorably in the news media.
Medtronic has higher revenue and earnings than Vertex Pharmaceuticals. Medtronic is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Medtronic received 31 more outperform votes than Vertex Pharmaceuticals when rated by MarketBeat users. Likewise, 76.53% of users gave Medtronic an outperform vote while only 75.65% of users gave Vertex Pharmaceuticals an outperform vote.
91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Vertex Pharmaceuticals has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.
Vertex Pharmaceuticals currently has a consensus target price of $429.45, suggesting a potential upside of 7.03%. Medtronic has a consensus target price of $94.91, suggesting a potential upside of 16.48%. Given Vertex Pharmaceuticals' higher possible upside, analysts plainly believe Medtronic is more favorable than Vertex Pharmaceuticals.
Vertex Pharmaceuticals has a net margin of 36.68% compared to Vertex Pharmaceuticals' net margin of 13.00%. Medtronic's return on equity of 21.91% beat Vertex Pharmaceuticals' return on equity.
Summary
Vertex Pharmaceuticals beats Medtronic on 10 of the 18 factors compared between the two stocks.
Get Medtronic News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medtronic Competitors List
Related Companies and Tools
